Clinical guidelines for the treatment of hypertension in African Americans

American Journal of Cardiovascular Drugs

Volumn 5, Issue 1, 2005, Pages 1-6

  Douglas, Janice G ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COCAINE; DECONGESTIVE AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; METHAMPHETAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN;

AFRICAN AMERICAN; ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COUGHING; DISEASE CONTROL; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; ETHNIC GROUP; EUROPEAN AMERICAN; EVIDENCE BASED MEDICINE; EXERCISE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFESTYLE; MEDICAL SOCIETY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; POTASSIUM INTAKE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RACE DIFFERENCE; REVIEW; SODIUM INTAKE; WEIGHT REDUCTION;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; HUMANS; HYPERTENSION; LIFE STYLE; PRACTICE GUIDELINES;

EID: 12744273519     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200505010-00001     Document Type: Review

References (42)

1. American Heart Association. 2000 Heart and stroke statistical update. Dallas (TX): American Heart Association, 2001
2. Sowers JR, Epstein M, Frolich E. Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001; 37: 1053-9
3. Fang J, Madhavan S, Alderman M. The association between birthplace and mortality from cardiovascular causes among black and white residents of New York City. N Engl J Med 1996; 335: 1545-51
4. Cooper R, Rotimi C. Hypertension in blacks. Am J Hypertens 1997; 10 (7 Pt 1): 804-12
5. Cappuccio FP, Cook DG, Atkinson RW, et al. Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London. Heart 1997; 78: 555-63
6. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-11
7. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: mortality by race, sex and blood pressure level. A further analysis. J Commun Health 1984; 9: 314-27
8. Clark LT. Improving compliance and increasing control of hypertension: needs of special hypertensive populations. Am Heart J 1991; 121: 664-9
9. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42 (6): 1206-52
10. Flack JM, Ferdinand KC, Nasser SA. Epidemiology of hypertension and cardiovascular disease in African Americans. J Clin Hypertens (Greenwich) 2003; 5 (1 Suppl. 1): 5-11
11. American Heart Association. 2003 Heart disease and stroke statistics update. Dallas (TX): American Heart Association, 2004
12. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996; 7: 481-90
13. Sullivan JM, Prewitte RL, Ratts TE. Sodium sensitivity in normotensive and borderline hypertensive humans. Am J Med Sci 1988; 295: 370-7
14. Weinberger M, Miller JZ, Luft FC, et al. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986; 8 (Suppl. 2): 127-34
15. Campese NM. Salt sensitivity in hypertension: renal and cardiovascular implications. Hypertension 1994; 23: 531-50
16. Bagazzi R, Stefanno B, Baldari D, et al. Microalbuminuria in salt-sensitive patients: a marker for renal and cardiovascular risk factors. Hypertension 1994; 23: 195-9
17. Campese VM, Parise M, Karubian F, et al. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 1991; 18: 805-12
18. Wright JT, Rahman M, Scarpa A. Determinants of salt-sensitivity in black and white normotensive and hypertensive women. Hypertension 2003 Dec; 42 (6): 1087-92
19. Weinberger M. Salt sensitivity is associated with an increased mortality in both normotensive and hypertensive humans. J Clin Hypertens 2002; 4: 274-6
20. Guidelines Subcommittee of the World Health Organization-International Society of Hypertension (WHO-ISH) Mild Hypertension Liaison Committee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83
21. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society of Hypertension in Blacks. Arch Intern Med 2003; 163: 525-41
22. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25: 199-201
23. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committee working Group. Am J Kidney Dis 2000; 36: 646-61
24. Maki DD, Ma JZ, Louis TA, et al. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-80
25. Klag MJ, Welton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-8
26. Welton PK, Parneger TV, He J, et al. The role of blood pressure as a risk factor for renal disease. J Hum Hypertens 1996; 10: 683-9
27. Powers DR, Wallin JD. End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Arch Intern Med 1998; 158: 793-800
28. Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African American population. Endocrinol Metab Clin North Am 1997; 26: 125-44
29. Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002; 288: 2421-31
30. Blaufox MD, Langford HG, Oberman A, et al. Effect of dietary change on the return of hypertension after withdrawal of prolonged antihypertensive therapy (DISH). J Hypertens Suppl 1984; 2 (3): S179-81
31. Brancati FL, Appel LJ, Seidler AJ, et al. Effect of potassium supplementation on blood pressure in African Americans on a low potassium diet. Arch Intern Med 1996; 156: 61-7
32. Appel LJ, Espeland MA, Easter L, et al. Effect of reduced sodium intake on hypertension control in older individuals. Arch Intern Med 2001; 161: 685-93
33. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-24
34. Sacks FM, Svedkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH): DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3-10
35. Wright JT, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American study of kidney disease and hypertension: African American Study of Kidney Disease and Hypertension Study Group. Arch Intern Med 2002; 162: 1636-43
36. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97
37. Weir MR, Saunders E. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans: Trandolapril Multicenter Study Group. J Hum Hypertens 1998; 12: 189-94
38. Elliott WJ. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther 1996; 60: 582-8
39. Buckhart DG, Brown NJ, Griffin MR, et al. Angiotensin converting enzyme-associated angioedema: higher risk in blacks than whites. Pharmacoepidemiol Drug Saf 1996; 5: 149-54
40. Jamerson K, Weir MR, Saunders E, et al. Comparison of the effects of valsartan HCT versus amlodipine on 24-hour ABPM blood pressure in African Americans with mild to moderate hypertension: the AADVANCE trial [abstract no. P-218]. Am J Hypertens 2004; 17 (5 Pt 2): 112-3
41. Flack JM, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. [published erratum appears in Clin Ther 2001; 23: 1922]. Clin Ther 2001; 23: 1193-208
42. Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/benazepril vs monotherapy of amlodipine in a practice-based setting. Am J Hypertens 2002; 15: 550-6